These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38323423)

  • 1. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
    Gilmartin CG; Hoyle N; Garjani A; Dixon T; Jos H; Paling D; Brownlee W; Tench C; Evangelou N
    Mult Scler; 2024 Apr; 30(4-5):600-604. PubMed ID: 38323423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.
    Krbot Skorić M; Rogić D; Lapić I; Šegulja D; Habek M
    Mult Scler Relat Disord; 2022 Jan; 57():103435. PubMed ID: 34920248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siponimod for multiple sclerosis.
    Cao L; Li M; Yao L; Yan P; Wang X; Yang Z; Lao Y; Li H; Yang K; Li K
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013647. PubMed ID: 34783010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
    Habek M; Junaković A; Karić A; Crnošija L; Barun B; Gabelić T; Adamec I; Krbot Skorić M
    Mult Scler Relat Disord; 2022 Aug; 64():103966. PubMed ID: 35724530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    Chang EH; Hardy TA
    J Neuroimmunol; 2024 Apr; 389():578330. PubMed ID: 38493554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
    Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The first russian experience of use of siponimod in real clinical practice].
    Prakhova LN; Ilves AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):138-141. PubMed ID: 35904305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
    Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
    Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
    Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    Spiezia AL; Scalia G; Petracca M; Caliendo D; Moccia M; Fiore A; Cerbone V; Lanzillo R; Brescia Morra V; Carotenuto A
    J Neurol; 2024 Jul; 271(7):4281-4291. PubMed ID: 38632126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
    J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
    Leavitt VM; Rocca M
    Neurology; 2021 Jan; 96(3):91-92. PubMed ID: 33328322
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N; Gudala K; Vudumula U; Vadapalle S; Bhadhuri A; Casanova A; Adlard N; Schwenkglenks M
    Pharmacoeconomics; 2021 May; 39(5):563-577. PubMed ID: 33791945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.
    Cortesi PA; Antonazzo IC; Gasperini C; Nica M; Ritrovato D; Mantovani LG
    PLoS One; 2022; 17(3):e0264123. PubMed ID: 35259168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.